NASDAQ:ALXN

Alexion Pharmaceuticals Stock Forecast, Price & News

$181.65
0.00 (0.00 %)
(As of 06/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$180.84
$182.20
50-Day Range
$152.35
$181.99
52-Week Range
$99.91
$182.72
Volume2.25 million shs
Average Volume2.45 million shs
Market Capitalization$40.15 billion
P/E Ratio59.36
Dividend YieldN/A
Beta1.28
30 days | 90 days | 365 days | Advanced Chart
Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Alexion Pharmaceuticals logo

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

501st out of 2,100 stocks

Pharmaceutical Preparations Industry

242nd out of 831 stocks

Analyst Opinion: 1.1Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

Is Alexion Pharmaceuticals a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. There are currently 15 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.
View analyst ratings for Alexion Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Alexion Pharmaceuticals?

Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alexion Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Alexion Pharmaceuticals
.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings data on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, topping the consensus estimate of $3.16 by $0.36. The biopharmaceutical company earned $1.64 billion during the quarter, compared to analyst estimates of $1.58 billion. Alexion Pharmaceuticals had a net margin of 10.89% and a trailing twelve-month return on equity of 23.43%. The company's revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.22 earnings per share.
View Alexion Pharmaceuticals' earnings history
.

How has Alexion Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALXN stock has increased by 116.8% and is now trading at $181.65.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALXN?

19 brokerages have issued twelve-month price objectives for Alexion Pharmaceuticals' shares. Their forecasts range from $73.00 to $205.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $159.32 in the next twelve months. This suggests that the stock has a possible downside of 12.3%.
View analysts' price targets for Alexion Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 58, Pay $4.25M) (LinkedIn Profile)
  • Dr. Aradhana Sarin M.D., Exec. VP & CFO (Age 46, Pay $1.75M) (LinkedIn Profile)
  • Mr. Brian M. Goff, Exec. VP and Chief Commercial & Global Operations Officer (Age 52, Pay $1.76M) (LinkedIn Profile)
  • Ms. Ellen V. Chiniara J.D., Esq., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 62, Pay $1.56M) (LinkedIn Profile)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 64, Pay $1.83M) (LinkedIn Profile)
  • Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
  • Mr. Christopher J. Stevo CFA, Head of Investor Relations
  • Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 49) (LinkedIn Profile)
  • Megan Goulart, Sr. Director of Corp. Communications
  • Ms. Becky Lillie, Interim Chief Human Experience Officer

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V).

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.94%), Pentwater Capital Management LP (1.94%), Baker BROS. Advisors LP (1.81%), Geode Capital Management LLC (1.80%), Renaissance Technologies LLC (1.51%) and Northern Trust Corp (1.23%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Tanisha Carino.
View institutional ownership trends for Alexion Pharmaceuticals
.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Janus Henderson Group PLC, Ameriprise Financial Inc., The Manufacturers Life Insurance Company, Amundi Asset Management US Inc., Bank of Montreal Can, Man Group plc, and Renaissance Technologies LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino.
View insider buying and selling activity for Alexion Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including Sculptor Capital LP, Pentwater Capital Management LP, Capitolis Advisors LLC, Paulson & CO. Inc., Bank of Nova Scotia, Omni Partners LLP, Franklin Resources Inc., and Boussard & Gavaudan Investment Management LLP.
View insider buying and selling activity for Alexion Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $181.65.

How much money does Alexion Pharmaceuticals make?

Alexion Pharmaceuticals has a market capitalization of $40.15 billion and generates $6.07 billion in revenue each year. The biopharmaceutical company earns $603.40 million in net income (profit) each year or $11.60 on an earnings per share basis.

How many employees does Alexion Pharmaceuticals have?

Alexion Pharmaceuticals employs 3,837 workers across the globe.

Does Alexion Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Alexion Pharmaceuticals: Syntimmune.

When was Alexion Pharmaceuticals founded?

Alexion Pharmaceuticals was founded in 1992.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

Where are Alexion Pharmaceuticals' headquarters?

Alexion Pharmaceuticals is headquartered at 121 SEAPORT BOULEVARD, BOSTON MA, 02210.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.